Terri B. Sebree
2022
In 2022, Terri B. Sebree earned a total compensation of $1.4M as President at Zynerba Pharmaceuticals, a 14% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $225,710 |
---|---|
Option Awards | $242,413 |
Salary | $486,236 |
Stock Awards | $409,700 |
Other | $17,204 |
Total | $1,381,263 |
Sebree received $486.2K in salary, accounting for 35% of the total pay in 2022.
Sebree also received $225.7K in non-equity incentive plan, $242.4K in option awards, $409.7K in stock awards and $17.2K in other compensation.
Rankings
In 2022, Terri B. Sebree's compensation ranked 2,404th out of 5,760 executives tracked by ExecPay. In other words, Sebree earned more than 58.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,404 out of 5,760 | 58th |
Division Manufacturing | 1,322 out of 3,136 | 58th |
Major group Chemicals And Allied Products | 591 out of 1,422 | 58th |
Industry group Drugs | 546 out of 1,323 | 59th |
Industry Pharmaceutical Preparations | 395 out of 969 | 59th |
Source: SEC filing on April 21, 2023.
Sebree's colleagues
We found two more compensation records of executives who worked with Terri B. Sebree at Zynerba Pharmaceuticals in 2022.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019